Acute Toxic Leukoencephalopathy: Etiologies, Imaging Findings, and Outcomes in 101 Patients

References

1. 1.↵
   2. Filley CM,
   3. Kleinschmidt-DeMasters BK

   . Toxic leukoencephalopathy. N Engl J Med 2001;345:425–32 doi:10.1056/NEJM200108093450606 pmid:11496854

   CrossRefPubMedWeb of Science
2. 2.↵
   2. McKinney AM,
   3. Kieffer SA,
   4. Paylor RT, et al

   . Acute toxic leukoencephalopathy: potential for reversibility clinically and on MRI with diffusion-weighted and FLAIR imaging. AJR Am J Roentgenol 2009;193:192–206 doi:10.2214/AJR.08.1176 pmid:19542414

   CrossRefPubMedWeb of Science
3. 3.↵
   2. Rimkus Cde M,
   3. Andrade CS,
   4. Leite Cda C, et al

   . Toxic leukoencephalopathies, including drug, medication, environmental, and radiation-induced encephalopathic syndromes. Semin Ultrasound CT MR 2014;35:97–117 doi:10.1053/j.sult.2013.09.005 pmid:24745887

   CrossRefPubMed
4. 4.↵
   2. Beitinjaneh A,
   3. McKinney AM,
   4. Cao Q, et al

   . Toxic leukoencephalopathy following fludarabine-associated hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011;17:300–08 doi:10.1016/j.bbmt.2010.04.003 pmid:20399878

   CrossRefPubMed
5. 5.↵
   2. Teksam M,
   3. Casey SO,
   4. Michel E, et al

   . Diffusion-weighted MR imaging findings in carbon monoxide poisoning. Neuroradiology 2002;44:109–13 doi:10.1007/s002340100639 pmid:11942360

   CrossRefPubMedWeb of Science
6. 6.↵
   2. Keogh CF,
   3. Andrews GT,
   4. Spacey SD, et al

   . Neuroimaging features of heroin inhalation toxicity: “chasing the dragon.” AJR Am J Roentgenol 2003;180:847–50 doi:10.2214/ajr.180.3.1800847 pmid:12591709

   CrossRefPubMedWeb of Science
7. 7.↵
   2. Sandoval C,
   3. Kutscher M,
   4. Jayabose S, et al

   . Neurotoxicity of intrathecal methotrexate: MR imaging findings. AJNR Am J Neuroradiol 2003;24:1887–90 pmid:14561622

   Abstract/FREE Full Text
8. 8.↵
   2. Lucato LT,
   3. McKinney AM,
   4. Short J, et al

   . Reversible findings of restricted diffusion in 5-fluorouracil neurotoxicity. Australas Radiol 2006;50:364–68 doi:10.1111/j.1440-1673.2006.01602.x pmid:16884425

   CrossRefPubMed
9. 9.↵
   2. McKinney AM,
   3. Lohman BD,
   4. Sarikaya B, et al

   . Acute hepatic encephalopathy: diffusion-weighted and fluid-attenuated inversion recovery findings, and correlation with plasma ammonia level and clinical outcome. AJNR Am J Neuroradiol 2010;31:1471–79 doi:10.3174/ajnr.A2112 pmid:20448015

   Abstract/FREE Full Text
10. 10.↵
    2. Kim E,
    3. Na DG,
    4. Kim EY, et al

    . MR imaging of metronidazole-induced encephalopathy: lesion distribution and diffusion-weighted imaging findings. AJNR Am J Neuroradiol 2007;28:1652–58 doi:10.3174/ajnr.A0655 pmid:17885234

    Abstract/FREE Full Text
11. 11.↵
    2. Casey SO,
    3. Sampaio RC,
    4. Michel E, et al

    . Posterior reversible encephalopathy syndrome: utility of fluid-attenuated inversion recovery MR imaging in the detection of cortical and subcortical lesions. AJNR Am J Neuroradiol 2000;21:1199–206 pmid:10954269

    Abstract/FREE Full Text
12. 12.↵
    2. McKinney AM,
    3. Short J,
    4. Truwit CL, et al

    . Posterior reversible encephalopathy syndrome: incidence of atypical regions of involvement and imaging findings. AJR Am J Roentgenol 2007;189:904–12 doi:10.2214/AJR.07.2024 pmid:17885064

    CrossRefPubMedWeb of Science
13. 13.↵
    2. Özütemiz C,
    3. Roshan SK,
    4. Kroll NJ, et al

    . Concomitant acute toxic leukoencephalopathy and posterior reversible encephalopathy syndrome. J Neuroimaging 2018;28:535–41 doi:10.1111/jon.12526 pmid:29797465

    CrossRefPubMed
14. 14.↵
    2. Karia SJ,
    3. Rykken JB,
    4. McKinney ZJ, et al

    . Utility and significance of gadolinium-based contrast enhancement in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol 2016;37:415–22 doi:10.3174/ajnr.A4563 pmid:26564441

    Abstract/FREE Full Text
15. 15.↵
    2. Banks JL,
    3. Marotta CA

    . Outcomes validity and reliability of the modified Rankin Scale: implications for stroke clinical trials—a literature review and synthesis. Stroke 2007;38:1091–96 doi:10.1161/01.STR.0000258355.23810.c6 pmid:17272767

    Abstract/FREE Full Text
16. 16.↵
    2. Bartlett E,
    3. Mikulis DJ

    . Chasing “chasing the dragon” with MRI: leukoencephalopathy in drug abuse. Br J Radiol 2005;78:997–1004 doi:10.1259/bjr/61535842 pmid:16249600

    Abstract/FREE Full Text
17. 17.↵
    2. Schuuring J,
    3. Wesseling P,
    4. Verrips A

    . Severe tacrolimus leukoencephalopathy after liver transplantation. AJNR Am J Neuroradiol 2003;24:2085–88 pmid:14625238

    Abstract/FREE Full Text
18. 18.↵
    2. Escamilla-Ocañas CE,
    3. Cámara-Lemarroy CR,
    4. Cantú-Martinez L, et al

    . Acute toxic leukoencephalopathy associated with a non-prescription weight loss supplement: a report of two cases. Neurol Sci 2017;38:2199–201 doi:10.1007/s10072-017-3028-0 pmid:28656377

    CrossRefPubMed
19. 19.↵
    2. Wolters EC,
    3. van Wijngaarden GK,
    4. Stam FC, et al

    . Leucoencephalopathy after inhaling “heroin” pyrolysate. Lancet 1982;2:1233–37 pmid:6128545

    PubMedWeb of Science
20. 20.↵
    2. Akiba T,
    3. Okeda R,
    4. Tajima T

    . Metabolites of 5-fluorouracil, alpha-fluoro-beta-alanine and fluoroacetic acid, directly injure myelinated fibers in tissue culture. Acta Neuropathol 1996;92:8–13 doi:10.1007/s004010050482 pmid:8811119

    CrossRefPubMed
21. 21.↵
    2. Shibutani M,
    3. Okeda R

    . Experimental study on subacute neurotoxicity of methotrexate in cats. Acta Neuropathol 1989;78:291–300 doi:10.1007/BF00687759 pmid:2763801

    CrossRefPubMed
22. 22.↵
    2. Okeda R,
    3. Shibutani M,
    4. Matsuo T, et al

    . Experimental neurotoxicity of 5-fluorouracil and its derivatives is due to poisoning by the monofluorinated organic metabolites, monofluoroacetic acid and alpha-fluoro-beta-alanine. Acta Neuropathol 1990;81:66–73 doi:10.1007/BF00662639 pmid:2128162

    CrossRefPubMed
23. 23.↵
    2. Aydin K,
    3. Donmez F,
    4. Tuzun U, et al

    . Diffusion MR findings in cyclosporin-a induced encephalopathy. Neuroradiology 2004;46:822–24 doi:10.1007/s00234-004-1258-3 pmid:15372219

    CrossRefPubMed
24. 24.↵
    2. Wilasrusmee C,
    3. Da Silva M,
    4. Singh B, et al

    . Morphological and biochemical effects of immunosuppressive drugs in a capillary tube assay for endothelial dysfunction. Clin Transplant 2003;17(Suppl 9):6–12 doi:10.1034/j.1399-0012.17.s9.1.x pmid:12795661

    CrossRefPubMedWeb of Science
25. 25.↵
    2. Lee MS,
    3. McKinney AM,
    4. Brace JR, et al

    . Clinical and imaging features of fludarabine neurotoxicity. J Neuroophthalmol 2010;30:37–41 doi:10.1097/WNO.0b013e3181ce8087 pmid:20182205

    CrossRefPubMed
26. 26.↵
    2. Kaiko RF,
    3. Wallenstein SL,
    4. Rogers A, et al

    . Relative analgesic potency of intramuscular heroin and morphine in cancer patients with postoperative pain and chronic pain due to cancer. NIDA Res Monogr 1981;34:213–19 pmid:6783935

    PubMed
27. 27.↵
    2. Offiah C,
    3. Hall E

    . Heroin-induced leukoencephalopathy: characterization using MRI, diffusion-weighted imaging, and MR spectroscopy. Clin Radiol 2008;63:146–52 doi:10.1016/j.crad.2007.07.021 pmid:18194689

    CrossRefPubMedWeb of Science
28. 28.↵
    2. Rykken JB,
    3. McKinney AM

    . Posterior reversible encephalopathy syndrome. Semin Ultrasound CT MR 2014;35:118–35 doi:10.1053/j.sult.2013.09.007 pmid:24745888

    CrossRefPubMed
29. 29.↵
    2. Jeon SB,
    3. Sohn CH,
    4. Seo DW, et al

    . Acute brain lesions on magnetic resonance imaging and delayed neurological sequelae in carbon monoxide poisoning. JAMA Neurol 2018;75:436–43 doi:10.1001/jamaneurol.2017.4618 pmid:29379952

    CrossRefPubMed
30. 30.↵
    2. Benson JC,
    3. Payabvash S,
    4. Thalken GL, et al

    . Delineation of microhemorrhage in acute hepatic encephalopathy using susceptibility-weighted imaging. Eur J Radiol 2016;85:629–34 doi:10.1016/j.ejrad.2015.12.025 pmid:26860677

    CrossRefPubMed
31. 31.↵
    2. Boggs JM

    . Myelin basic protein: a multifunctional protein. Cell Mol Life Sci 2006;63:1945–61 doi:10.1007/s00018-006-6094-7 pmid:16794783

    CrossRefPubMedWeb of Science
32. 32.↵
    2. Whitaker JN

    . Myelin basic protein in cerebrospinal fluid and other body fluids. Mult Scler 1998;4:16–21 pmid:9532587

    CrossRefPubMedWeb of Science
33. 33.↵
    2. Fan R,
    3. Schrott LM,
    4. Arnold T, et al

    . Chronic oxycodone induces axonal degeneration in rat brain. BMC Neurosci 2018;19:15 doi:10.1186/s12868-018-0417-0 pmid:29571287

    CrossRefPubMed
34. 34.↵
    2. Kim DM,
    3. Lee IH,
    4. Song CJ

    . Uremic encephalopathy: MR imaging findings and clinical correlation. AJNR Am J Neuroradiol 2016;37:1604–09 doi:10.3174/ajnr.A4776 pmid:27127003

    Abstract/FREE Full Text
35. 35.↵
    2. Kang E,
    3. Jeon SJ,
    4. Choi SS

    . Uremic encephalopathy with atypical magnetic resonance features on diffusion-weighted images. Korean J Radiol 2012;13:808–11 doi:10.3348/kjr.2012.13.6.808 pmid:23118581

    CrossRefPubMed
36. 36.↵
    2. Drew DA,
    3. Koo BB,
    4. Bhadelia R, et al

    . White matter damage in maintenance hemodialysis patients: a diffusion tensor imaging study. BMC Nephrol 2017;18:213 doi:10.1186/s12882-017-0628-0 pmid:28676035

    CrossRefPubMed
37. 37.↵
    2. Bugnicourt JM,
    3. Godefroy O,
    4. Chillon JM, et al

    . Cognitive disorders and dementia in CKD: the neglected kidney-brain axis. J Am Soc Nephrol 2013;24:353–63 doi:10.1681/ASN.2012050536 pmid:23291474

    Abstract/FREE Full Text